Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06191198 · ClinicalTrials.gov registry record · Phase 2
Communication Bridge 3 Study
A Phase 2 study of Primary Progressive Aphasia, sponsored by University of Chicago.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
- 1
- Study location
NCT06191198: Recruiting Phase 2 study of Primary Progressive Aphasia, sponsored by University of Chicago.
NCT06191198 is a Phase 2 study of Primary Progressive Aphasia that is actively recruiting participants, run by University of Chicago. The registered enrollment target is 200 participants, above the 79-participant average among 15 other Primary Progressive Aphasia trials with a reported enrollment target (153% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06191198, a Phase 2 study of Primary Progressive Aphasia, is actively recruiting participants, sponsored by University of Chicago.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will use a randomized controlled trial design to evaluate the effect of two evidence-based treatments for adults with mild-moderate Primary Progressive Aphasia (PPA). The aim of the study is to help us better understand the effects of speech-language therapy on communication abilities in individuals with PPA.
Primary Outcome
Goal Attainment Scaling, a 7-point rating scale with -3 representing 'no longer participating' and +3 representing 'exceeded goal'. Higher scores indicate better progress in goal achievement.
Conditions Studied
Interventions
- BEHAVIORAL Communication Bridge™
- BEHAVIORAL Evidence-Based Impairment Focused
Study Locations (1)
Illinois
- University of Chicago - American School Building - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2024-08-23 |
| Est. Completion | 2028-07-15 |
| Phase | Phase 2 |
What NCT06191198 shows while recruiting
NCT06191198 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, above the 79-participant average among 15 other Primary Progressive Aphasia trials with a reported enrollment target (153% higher).
The record links to 1 condition, with Primary Progressive Aphasia appearing as the primary indexed condition, and to 2 interventions - of which Communication Bridge™ is the first listed.
NCT06191198 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT06191198 about?
NCT06191198 is a clinical study titled "Communication Bridge 3 Study". This study will use a randomized controlled trial design to evaluate the effect of two evidence-based treatments for adults with mild-moderate Primary Progressive Aphasia (PPA). The aim of the study is to help us better understand the effects of speech-language therapy on communication abilities in ...
What is the current status of trial NCT06191198?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2024-08-23. Estimated completion is 2028-07-15.
What conditions does trial NCT06191198 study?
This clinical trial studies the following conditions: Primary Progressive Aphasia.
What interventions are being tested in trial NCT06191198?
The interventions under investigation include: Communication Bridge™ (BEHAVIORAL), Evidence-Based Impairment Focused (BEHAVIORAL).
Who is sponsoring clinical trial NCT06191198?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06191198 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Progressive Aphasia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06191198's enrollment target sits among peer trials
200 2nd of 15 the highest of 15 other Primary Progressive Aphasia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Primary Progressive Aphasia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Transcranial Direct Current Stimulation in the Treatment of Primary Progressive Aphasia
RECRUITING · Phase 2
-
Longitudinal Multi-Modality Imaging in Progressive Apraxia of Speech
RECRUITING · Phase 4
-
The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech
RECRUITING
-
Language in Primary Progressive Aphasia
RECRUITING
-
Educational Support Group Program for Bilingual and Spanish-speaking Carepartners and People With Progressive Aphasia
RECRUITING · Early Phase 1
-
Enhancing Language Function in Aphasia
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI